To obtain further information on the tolerability and efficacy of Atrovent® inhalets in the treatment of Chronic Obstructive Pulmonary Disease under conditions of daily practice
Study Type
OBSERVATIONAL
Enrollment
346
Investigator assessment of improvement of the clinical picture rated on a 6-point symptom profile
Time frame: Up to 4 weeks after first drug administration
Assessment of efficacy by investigator on a 4-point scale
Time frame: Up to 4 weeks after first drug administration
Assessment of efficacy by patient on a 4-point scale
Time frame: Up to 4 weeks after first drug administration
Assessment of tolerability by investigator on a 4-point scale
Time frame: Up to 4 weeks after first drug administration
Assessment of tolerability by patient on a 4-point scale
Time frame: Up to 4 weeks after first drug administration
Number of patients with adverse drug reactions
Time frame: Up to 4 weeks after first drug administration
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.